参考文献/References:
［1］La Marca A, Sighinolfi G, Radi D, et al.Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART) ［J］. Hum Reprod Update，2010，16（2）:113–130.
［2］Broer SL, Dolleman M, Opmeer BC, et al. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation:a meta-analysis ［J］. Hum Reprod Update, 2011(17): 46–54.
［3］Iliodromiti S, Kelsey TW, WU O, et al. The predictive accuracy of anti-Mullerian hormone for live birth after assisted conception:a systematic review and meta-analysis of the literature［J］. Hum Reprod Update, 2014(20): 560–570.
［4］Broer SL, Van Disseldorp J, Broeze KA, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach ［J］. Hum Reprod Update, 2012, 19 (1): 26-36.
［5］Sunkara SK, Khalaf Y, Maheshwari A, et al. Association between response to ovarian stimulation and miscarriage following IVF:an analysis of 124 351 IVF pregnancies［J］. Hum Reprod, 2014(29): 1218–1224.
［6］Rombauts L, Lambalk CB, Schultze-Mosgau A, et al. Intercycle variability of the ovarian response in patients undergoing repeated stimulation with corifollitropin alfa in a gonadotropin-eleasing hormone antagonist protocol ［J］. Fertil Steril, 2015, 104(4): 884-890.
［7］Brodin T, Hadziosmanovic N, Berglund L, et al. Comparing four ovarian reserve markers-associations with ovarian response and live births after assisted reproduction ［J］. Acta Obstet Gynecol Scand, 2015, 4(10): 1056-1063.
［8］Polyzos NP, Sunkara SK.Sub-optimal responders following controlled ovarian stimulation: an overlooked group? ［J］.Hum Reprod，2015，30(9)：2005-2008.
［9］Shrestha D, LA Xiaolin, Feng HL. Comparison of different stimulation protocols used in in vitro fertilization: a review［J］. Annals of translational medicine, 2015, 3(10): 137.
［10］Revelli A, Pettinau G, Basso G, et al. Controlled ovarian stimulation with recombinant-FSH plus recombinant-LH vs. human menopausal gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population ［J］. Reproductive Biology and Endocrinology, 2015,13(1):1-8.
［11］Gingold JA, Lee JA, Whitehouse MC, et al. Maximum basal FSH predicts reproductive outcome better than cycle-specific basal FSH levels:waiting for a "better" month conveys limited retrieval benefits ［J］.Reproductive Biology and Endocrinology, 2015,13 (1):1-14.
［12］Baker VL, Brown MB, Luke B, et al. Gonadotropin dose is negatively correlated with live birth rate:analysis of more than 650,000 assisted reproductive technology cycles ［J］. Fertil Steril, 2015, 104 (5): 1145-1152.
［13］Lainas TG, Sfontouris IA, Venetis CA, et al. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders ［J］. Hum Reprod, 2015, 30 (10): 2321-2330.
［14］Lefebvre J, Antaki R, Kadoch IJ, et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders:a randomized controlled trial［J］. Fertil Steril, 2015, 104(6): 1419-1425.
［15］Maheshwari A, Gibreel A, Siristatidis CS, et al. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction ［J］. Cochrane Database Syst Rev, 2015,66(8):1305-1305.
［16］Drakopoulos P, Blockeel C, Stoop D, et al. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI.How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? ［J］. Hum Reprod, 2016, 31(2): 370-376.
［17］Pacchiarotti A, Selman H, Valeri CA, et al. Ovarian stimulation protocol in IVF: an Up-to-Date review of the literature［J］. Curr Pharm Biotechnol, 2016, 17(4): 303-315.
［18］Mclernon DJ, Maheshwari A, Lee AJ. Cumulative live birth rates after one or more complete cycles of IVF: a population-based study of linked cycle data from 178 898 women［J］. Human Reproduction, 2016, 31(3): 572-581.
［19］Bosch E, Labarta E, Kolibianakis EA, et al. Regimen of ovarian stimulation affects oocyte and therefore embryo quality［J］. Fertil Steril, 2016, 105(3): 560-570.
［20］Shavit T, Shalom-Paz E, Samara N, et al. Comparison between stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF with GnRH antagonist protocol［J］. Gynecological Endocrinology, 2016, 32(8): 629-633.
［21］Toftager M, Bogstad J, Bryndorf T, et al. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles［J］. Human Reproduction, 2016, 31(6): 1253-1264.
［22］Youssef M, Abou-Setta AM, Lam WS. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles［J］.Cochrane Database of Systematic Reviews, 2011,4 (4):CD003719.
［23］Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology ［J］. Fertility & Sterility,2011,96(3):S261.
［24］Humaidan P, Nelson SM, Devroey P, et al. Ovarian hyperstimulation syndrome:review and new classification criteria forreporting in clinical trials［J］. Hum Reprod, 2016, 31(9): 1997-2004.
［25］Kotanidis L, Nikolettos K, Petousis S, et al. The use of serum anti-Mullerian hormone (AMH) levels and antral follicle count (AFC) to predict the number of oocytes collected and availability of embryos for cryopreservation in IVF［J］. J Endocrinol Invest, 2016, 39 (12): 1459-1464.
［26］Song D, Shi Y, Zhong Y, et al. Efficiency of mild ovarian stimulation with clomiphene on poor ovarian responders during IVF/ICSI procedures: a meta-analysis ［J］.Eur J Obstet Gynecol Reprod Biol,2016,204 （8）:36-43.
［27］Sunkara SK, Lamarca A, Polyzos NP, et al. Live birth and perinatal outcomes following stimulated and unstimulated IVF: analysis of over two decades of a nationwide data［J］. Human Reproduction, 2016, 31(10): 2261-2267.
［28］Schwarze JE, Crosby JA, Zegers-Hochschild F. Addition of neither recombinant nor urinary luteinizing hormone was associated with an improvement in the outcome of autologous in vitro fertilization/intracytoplasmatic sperm injection cycles under regular clinical settings:a multicenter observational analysis［J］. Fertil Steril, 2016, 106 (7): 1714-1717.
［29］Youssef M, Van Wely M, Al-Inany H, et al. A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF:a multicenter randomized non-inferiority trial［J］.Hum Reprod, 2017, 32(1): 112-118.
［30］Nyboe Andersen A, Nelson SM, Fauser BC, et al. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial ［J］.Fertil Steril，2016，106(16)：62956-62964.
［31］Vaughan DA, Leung A, Resetkova N, et al. How many oocytes are optimal to achieve multiple live births with one stimulation cycle? The one and done approach［J］. Fertil Steril，2016，106(16)：62960-62966.
相似文献/References:
[1]姜荣华,钟小英,潘萍,等.61例多囊卵巢综合征妇女行供精人工授精结局分析[J].中国计划生育和妇产科,2011,(04):0.
JIANG Rong-hua,ZHONG Xiao-ying,PAN Ping.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(2):0.
[2]刘振腾,郝翠芳.有生育要求的多囊卵巢综合征患者的治疗[J].中国计划生育和妇产科,2014,(04):0.
LIU Zhen-teng,HAO Cui-fang,Reproductive Medical Center,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2014,(2):0.
[3]王亚丛,王丽,喻琳麟,等.轻度子宫内膜异位症合并不孕症患者术后促排卵对妊娠的影响[J].中国计划生育和妇产科,2014,(05):0.
WANG Ya-cong,WANG Li,YU Lin-lin,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2014,(2):0.
[4]李尚为.多囊卵巢综合征的促排卵治疗[J].中国计划生育和妇产科,2014,(06):0.
[5]尹敏娜,刘春林,刘俊,等.影响促排卵宫腔内人工授精临床妊娠率相关因素分析[J].中国计划生育和妇产科,2016,(05):0.
YIN Min-na,LIU Chun-lin,LIU Jun,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2016,(2):0.
[6]王利群,李萌,卢美松*.控制性超促排卵中新发子宫内膜息肉的研究进展[J].中国计划生育和妇产科,2017,(8):5.
[7]莫晓嫦*,王建,冯兰青,等.甲状腺过氧化物酶抗体水平对促甲状腺激素正常的多囊卵巢综合征不孕患者促排卵效果及妊娠成功率的预测价值[J].中国计划生育和妇产科,2019,(7):45.
MO Xiao-chang*,WANG Jian,FENG Lan-qing,et al.Predicting value of TPOAb level in ovulation induction and pregnancy success rate in patients with PCOS infertility with normal TSH[J].Chinese Journal of Family Planning & Gynecotokology,2019,(2):45.